Diffusion Pharmaceuticals Inc  

(Public, OTCMKTS:DFFN)   Watch this stock  
Find more results for DiFusion, Inc
0.900
0.000 (0.00%)
Jul 21 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.40 - 2.60
Open     -
Vol / Avg. 0.00/2,606.00
Mkt cap 89.69M
P/E     -
Div/yield     -
EPS -1.15
Shares 102.43M
Beta -0.20
Inst. own 1%
Jun 21, 2016
Diffusion Pharmaceuticals Inc at JMP Securities Life Sciences Conference
May 16, 2016
Q1 2016 Diffusion Pharmaceuticals Inc Earnings Release
  

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -198.20% -105.74%
Return on average equity -301.88% -124.96%
Employees 8 -
CDP Score - -

Address

2020 Avon Ct Ste 4
CHARLOTTESVILLE, VA 22902-8734
United States - Map
+1-434-2200718 (Phone)
+1-434-2200722 (Fax)

Website links

Description

Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company's Diffusion's technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases.